Company registration number 15228881 (England and Wales)
SAVILLEX LIFE SCIENCES UK LIMITED
FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024
PAGES FOR FILING WITH REGISTRAR
SAVILLEX LIFE SCIENCES UK LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 5
SAVILLEX LIFE SCIENCES UK LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 1 -
2024
Notes
£
£
Fixed assets
Investments
4
45,178,969
Creditors: amounts falling due after more than one year
6
(45,034,619)
Net assets
144,350
Capital and reserves
Called up share capital
7
2
Share premium account
144,348
Total equity
144,350

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 26 September 2025 and are signed on its behalf by:
M C Arnold
Director
Company registration number 15228881 (England and Wales)
SAVILLEX LIFE SCIENCES UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2024
- 2 -
1
Accounting policies
Company information

Savillex Life Sciences UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is First Floor Templeback, 10 Temple Back, Bristol, United Kingdom, BS1 6FL.

1.1
Reporting period

The financial statements cover a 15-month period from the date of incorporation, 23 October 2023, to 31 December 2024. The year-end of 31 December 2024 was selected to align with the group’s reporting year-end.

1.2
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

The company has taken advantage of the exemption under section 400 of the Companies Act 2006 not to prepare consolidated accounts. The financial statements present information about the company as an individual entity and not about its group.

 

Savillex Life Sciences UK Limited is a wholly owned subsidiary of Savillex LLC and the results of Savillex Life Sciences UK Limited are included in the consolidated financial statements of Savillex LLC which are available from their registered office 10321 W 70th St, Eden Prairie, MN 55344.

1.3
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.4
Fixed asset investments

Interests in subsidiaries entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

SAVILLEX LIFE SCIENCES UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 3 -
Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

1.6
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

 

The directors deem that there are no judgements or estimates that are considered critical or key.

3
Employees

The company does not employ any staff, the business and administration of the company is being carried out

by staff of other group undertakings.

SAVILLEX LIFE SCIENCES UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2024
- 4 -
4
Fixed asset investments
2024
£
Shares in group undertakings and participating interests
45,178,969
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 23 October 2023
-
Additions
45,178,969
At 31 December 2024
45,178,969
Carrying amount
At 31 December 2024
45,178,969
5
Subsidiaries

Details of the company's subsidiaries at 31 December 2024 are as follows:

Name of undertaking
Address
Class of
% Held
shares held
Direct
Indirect
On Newco Limited (1)
England and Wales
Ordinary
100.00
-
Onfab Limited (1)
England and Wales
Ordinary
0
100.00
On Containment Solutions SL
Spain
Ordinary
0
100.00

Registered office addresses (all UK unless otherwise indicated):

1
Unit 6 & 7 Prosperity Court, Prosperity Way, Middlewich, CW10 0GD
6
Creditors: amounts falling due after more than one year
2024
£
Amounts owed to group undertakings
45,034,619
7
Called up share capital
2024
2024
Ordinary share capital
Number
£
Issued and fully paid
Ordinary shares of £1 each
2
2
SAVILLEX LIFE SCIENCES UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2024
- 5 -
8
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

Senior Statutory Auditor:
Stephen Grayson ACA FCCA
Statutory Auditor:
Cooper Parry Group Limited
Date of audit report:
26 September 2025
9
Parent company

The ultimate parent company is Savillex LLC, a company registered in the USA. The consolidated financial statements of the group may be obtained from Savillex LLC registered office 10321 W 70th St, Eden Prairie, MN 55344.

2024-12-312023-10-23falsefalsefalse26 September 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityM C ArnoldMr I J DonaldM B ScherrerD L PotterS A AbramsJ R AielloM C Arnold152288812023-10-232024-12-31152288812024-12-3115228881core:ShareCapital2024-12-3115228881core:SharePremium2024-12-3115228881core:ShareCapitalOrdinaryShareClass12024-12-3115228881bus:CompanySecretaryDirector12023-10-232024-12-3115228881core:Subsidiary12023-10-232024-12-3115228881core:Subsidiary22023-10-232024-12-3115228881core:Subsidiary32023-10-232024-12-3115228881core:Subsidiary112023-10-232024-12-3115228881core:Subsidiary222023-10-232024-12-3115228881core:Subsidiary332023-10-232024-12-3115228881core:Non-currentFinancialInstruments2024-12-3115228881bus:OrdinaryShareClass12023-10-232024-12-3115228881bus:OrdinaryShareClass12024-12-3115228881bus:PrivateLimitedCompanyLtd2023-10-232024-12-3115228881bus:SmallCompaniesRegimeForAccounts2023-10-232024-12-3115228881bus:FRS1022023-10-232024-12-3115228881bus:Audited2023-10-232024-12-3115228881bus:Director12023-10-232024-12-3115228881bus:Director22023-10-232024-12-3115228881bus:Director32023-10-232024-12-3115228881bus:Director42023-10-232024-12-3115228881bus:Director52023-10-232024-12-3115228881bus:Director62023-10-232024-12-3115228881bus:CompanySecretary12023-10-232024-12-3115228881bus:FullAccounts2023-10-232024-12-31xbrli:purexbrli:sharesiso4217:GBP